In particular, the interaction between the biological (monoclonal antibody) treatment Herceptin with HER2 receptors on cancer cell surfaces and the sensitivity of cancer cells to the chemotherapeutic agent DXR was considered alongside the effect of glycosylation on cancer cell sensitivity to the growth factors EGF and IGF-1. The gene discussed is IGF1; the disease is cancer.